

## HEXIMA ANTIFUNGAL COLLABORATION UPDATE

Acrux announced in November 2013 that it had entered into a collaboration agreement with Hexima Limited to develop and commercialise a medical product to treat fungal infections.

In February 2014 it was announced that encouraging data had been generated, that the next stage of product development had been initiated, and that patent applications were being prepared. Acrux recently filed an Australian provisional patent application to protect the joint rights of Acrux and Hexima to the intellectual property resulting to date from the collaboration.

Hexima has subsequently advised that it considers the collaborative venture to have concluded and, that it may not wish to further explore commercialisation of the antifungal medical product with Acrux.

Acrux considers the best way to commercialise the technology remains through our collaboration agreement with Hexima and is continuing to press for this to occur.

### Contact

Tony Di Pietro, Chief Financial Officer and Company Secretary: 03 8379 0100

### About Acrux

- Acrux is an Australian drug delivery company, developing and commercialising a range of patient-preferred, patented pharmaceutical products for global markets, using its innovative technology to administer drugs through the skin.
- The Acrux technology, used in marketed products including Axiron®, Evamist® and Recuvyra™, is based on a fast-drying, small volume, accurately dosed solution, containing penetration enhancers, that when applied topically, deposits drug through the skin for long acting delivery.
- Acrux has three products marketed by licensees in the USA, three products approved in Europe, and further products at earlier stages of development